BALTIMORE and HAMBURG, Germany, April 9, 2013 /PRNewswire/ --
A study presented at the AACR Annual Meeting 2013 indicates that a DNA blood test using Inostics’ BEAMing Digital PCR can detect more mutations associated with secondary drug resistance in GIST patients than testing conventional biopsies.
Therapies targeted to specific cancer-causing mutations may be the most promising strategy in cancer treatment. However, inter- and intra-tumor heterogeneity pose a significant challenge to maximizing therapeutic efficacy. Within a single patient, different cancer cells may have different sets of mutations making it very difficult to detect all of the relevant mutations in a single tissue biopsy.
“To develop the right drug for the right patient, and to use those drugs most effectively, we need to understand the tumor burden in patients as fully as possible. Inostics’ BEAMing technology may offer physicians a real-time composite picture of all the mutations across all tumors in any given patient using just a simple blood sample”, George D. Demetri, M.D., Director of the Ludwig Center at Dana-Farber Cancer Institute and Harvard Medical School in Boston, Mass., said.
Demetri refers to data from a sub-analysis of the phase III GIST-Regorafenib in Progressive Desease (GRID) trial, designed to assess the efficacy of regorafenib in patients with GIST. Comparing conventional sequencing on tumor tissue with data generated using the BEAMing technology on blood samples they found resistance mutations 4 times more often in blood samples (48%) than in tumor tissue samples (12%). Furthermore, nearly half of the blood samples that had secondary KIT mutations harbored multiple secondary mutations. “By using this technology we hope to develop the most rational drug combinations and better tests to match patients with the most effective therapies going forward”, Demetri said.
BEAMing technology is a combination of digital PCR and flow cytometry originally developed by the group of Bert Vogelstein, M.D. at The Johns Hopkins University. Inostics licensed the technology and adopted it for routine use. Understanding the need of even more comprehensive coverage for the detection of de novo resistance mutations, Inostics is currently developing a sequencing based technology. “We are combining our expertise for highly sensitive mutation detection using BEAMing with the power of sequencing to hopefully detect all potential primary and secondary resistant mutations in the KIT gene in the near future” said Philipp Angenendt, Ph.D., Chief Technology Officer of Inostics.
BEAMing is the most sensitive and quantitative technology available today for the detection of tumor specific somatic mutations in blood samples. Inostics’ BEAMing services are readily available to support clinical trials and research in oncology and have been successfully used on over 5000 samples in >34 clinical trials. Furthermore, Inostics offers BEAMing as a CLIA certified laboratory developed test for routine clinical analysis.
For more information on blood testing and the BEAMing Digital PCR technology refer to http://www.inostics.com or email us at info@inostics.com
